• Je něco špatně v tomto záznamu ?

Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA)

M. Joerger, S. Diem, N. Wyss, KL. Koster, L. Besse, D. Hess, Y. Metaxas, MC. Flynn, S. Aeppli, MT. Abou, T. Philip El Saadan, S. Mane, E. Hiendlmeyer, R. von Moos, L. Flatz

. 2025 ; 35 (4) : 252-258. [pub] 20250417

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, klinické zkoušky, fáze I

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015137

Tinostamustine is a first-in-class alkylating deacetylase inhibitor that facilitates access to cancer cell DNA, resulting in its damage and counteracting DNA repair systems. We hypothesize that the addition of tinostamustine to immune checkpoint inhibitors (ICIs) improves melanoma treatment. This open-label, nonrandomized phase IB study characterized dose-limiting toxicity (DLT) and the recommended dose (RD) of 2-weekly intravenous tinostamustine at escalating doses of 15 and 30 mg/m 2 when administered with 2-weekly nivolumab 3 mg/kg added in cycle 2 in patients with melanoma. We included 17 patients (four at 15 mg/m 2 and 13 at 30 mg/m 2 tinostamustine). A total of 13/17 (77%) patients were ICI-resistant, 7/17 (41%) had unfavorable melanoma subtypes. No DLT was identified. Tinostamustine RD was 30 mg/m 2 every 2 weeks. One patient experienced grade 2 nivolumab-associated immune-related pneumonitis. Tinostamustine-associated grade 3 leukocytopenia was documented in one patient, grade 2 leukocytopenia in five patients, and grade 1 thrombocytopenia in three patients. Treatment discontinuation occurred in one patient for nivolumab-associated immune-related pneumonitis and in another patient for tumor-related hemorrhage. A total of 7/13 (54%) evaluable patients had at least stable disease as best treatment response, including 3/13 (23%) patients with a confirmed partial response. Median progression-free survival was 8.3 weeks [95% confidence interval (CI): 2.4-15.4 weeks), median overall survival was 19.1 weeks (95% CI: 2.4-41 weeks). Two-weekly intravenous tinostamustine at an immune-modulatory dose of 30 mg/m 2 is safe when coadministered with nivolumab 3 mg/kg and resulted in 54% disease stabilization and 23% confirmed partial responses in patients with predominantly ICI-resistant, advanced melanoma.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015137
003      
CZ-PrNML
005      
20250731090800.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1097/CMR.0000000000001040 $2 doi
035    __
$a (PubMed)40265641
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Joerger, Markus $u Department of Medical Oncology and Hematology, Cantonal Hospital, St.Gallen $u Medical School, University Hospital, Basel
245    10
$a Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA) / $c M. Joerger, S. Diem, N. Wyss, KL. Koster, L. Besse, D. Hess, Y. Metaxas, MC. Flynn, S. Aeppli, MT. Abou, T. Philip El Saadan, S. Mane, E. Hiendlmeyer, R. von Moos, L. Flatz
520    9_
$a Tinostamustine is a first-in-class alkylating deacetylase inhibitor that facilitates access to cancer cell DNA, resulting in its damage and counteracting DNA repair systems. We hypothesize that the addition of tinostamustine to immune checkpoint inhibitors (ICIs) improves melanoma treatment. This open-label, nonrandomized phase IB study characterized dose-limiting toxicity (DLT) and the recommended dose (RD) of 2-weekly intravenous tinostamustine at escalating doses of 15 and 30 mg/m 2 when administered with 2-weekly nivolumab 3 mg/kg added in cycle 2 in patients with melanoma. We included 17 patients (four at 15 mg/m 2 and 13 at 30 mg/m 2 tinostamustine). A total of 13/17 (77%) patients were ICI-resistant, 7/17 (41%) had unfavorable melanoma subtypes. No DLT was identified. Tinostamustine RD was 30 mg/m 2 every 2 weeks. One patient experienced grade 2 nivolumab-associated immune-related pneumonitis. Tinostamustine-associated grade 3 leukocytopenia was documented in one patient, grade 2 leukocytopenia in five patients, and grade 1 thrombocytopenia in three patients. Treatment discontinuation occurred in one patient for nivolumab-associated immune-related pneumonitis and in another patient for tumor-related hemorrhage. A total of 7/13 (54%) evaluable patients had at least stable disease as best treatment response, including 3/13 (23%) patients with a confirmed partial response. Median progression-free survival was 8.3 weeks [95% confidence interval (CI): 2.4-15.4 weeks), median overall survival was 19.1 weeks (95% CI: 2.4-41 weeks). Two-weekly intravenous tinostamustine at an immune-modulatory dose of 30 mg/m 2 is safe when coadministered with nivolumab 3 mg/kg and resulted in 54% disease stabilization and 23% confirmed partial responses in patients with predominantly ICI-resistant, advanced melanoma.
650    _2
$a lidé $7 D006801
650    12
$a nivolumab $x farmakologie $x terapeutické užití $x aplikace a dávkování $7 D000077594
650    12
$a melanom $x farmakoterapie $x patologie $7 D008545
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x farmakologie $7 D000971
650    _2
$a dospělí $7 D000328
650    12
$a nádory kůže $x farmakoterapie $x patologie $7 D012878
650    _2
$a senioři nad 80 let $7 D000369
655    _2
$a časopisecké články $7 D016428
655    _2
$a klinické zkoušky, fáze I $7 D017426
700    1_
$a Diem, Stefan $u Department of Medical Oncology and Hematology, Cantonal Hospital, St.Gallen $u Department of Internal Medicine, Regional Hospital, Grabs
700    1_
$a Wyss, Nina $u Department of Dermatology, Institute of Immunobiology, St.Gallen $u Department of Dermatology
700    1_
$a Koster, Kira-Lee $u Department of Medical Oncology and Hematology, Cantonal Hospital, St.Gallen
700    1_
$a Besse, Lenka $u Department of Oncology and Hematology, Laboratory of Experimental Oncology, Cantonal Hospital, St.Gallen, Switzerland $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Hess, Dagmar $u Department of Medical Oncology and Hematology, Cantonal Hospital, St.Gallen
700    1_
$a Metaxas, Yannis $u Department of Oncology/Hematology, Spital Thurgau, Frauenfeld
700    1_
$a Flynn, Marie-Claire $u Department of Medical Oncology and Hematology, Cantonal Hospital, St.Gallen
700    1_
$a Aeppli, Stefanie $u Department of Medical Oncology and Hematology, Cantonal Hospital, St.Gallen
700    1_
$a Abou, Marie Therese $u Department of Dermatology, Institute of Immunobiology, St.Gallen
700    1_
$a Philip El Saadan, Taemer $u Cancer Center, Cantonal Hospital, Chur, Switzerland
700    1_
$a Mane, Shrunal $u Department of Dermatology, University Hospital, Tübingen, Germany
700    1_
$a Hiendlmeyer, Elke $u Clinical Trial Unit (CTU), Cantonal Hospital, St.Gallen, Switzerland
700    1_
$a von Moos, Roger $u Cancer Center, Cantonal Hospital, Chur, Switzerland
700    1_
$a Flatz, Lukas $u Department of Dermatology, Institute of Immunobiology, St.Gallen $u Department of Dermatology $u Department of Dermatology, University Hospital, Tübingen, Germany
773    0_
$w MED00003323 $t Melanoma research $x 1473-5636 $g Roč. 35, č. 4 (2025), s. 252-258
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40265641 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090755 $b ABA008
999    __
$a ok $b bmc $g 2366168 $s 1252262
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 35 $c 4 $d 252-258 $e 20250417 $i 1473-5636 $m Melanoma research $n Melanoma Res $x MED00003323
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace